Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have studied eight men with moderate hypertension to determine the
atrial natriuretic peptide
(alpha-hANP) response to acute volume expansion. Rapid infusion of 1,000 ml 0.9% saline (10-20 min) caused an increase in central venous pressure (4.7 +/- 1.6 cmH2O) while blood pressure and pulse pressure (arterial baroreceptor load) did not change.
Stroke
volume and heart rate were not affected by the volume load but plasma renin activity (PRA) was significantly suppressed (from 0.83 +/- 0.14 to 0.68 +/- 0.34 microgram AI I/ml-h; p less than 0.01). A significant hemodilution was also observed. Renal sodium excretion was significantly increased. Arterial alpha-hANP increased significantly from 21.1 +/- 6.1 to 30.5 +/- 4.0 pmol/l (p less than 0.02) during volume expansion. There was a significant correlation between corrected plasma volume increase (urine volume subtracted from the infused volume) and alpha-hANP plasma elevation (r = 0.78; p less than 0.05). There was also a significant negative correlation between changes alpha-hANP and PRA (r = -0.78, p less than 0.05). We conclude that only moderate volume loading in human hypertensives is a mechanism for increase in plasma alpha-hANP levels. The significant negative correlation between changes in alpha-hANP and PRA suggests that alpha-hANP may be the humoral factor at least partly responsible for suppression of renin in hypertensive man. Since increased fluid volume also affects sympathetic renal efferents as well as vasopressin secretion, our observed relationship between volume load and renin may well be related also to such mechanisms.
...
PMID:Significant relationship between renin suppression and atrial natriuretic peptide (alpha-hANP) during volume loading in hypertensive men. 295 32
Hemodynamic, renal, and hormonal effects of intravenous bolus injection of 50 micrograms synthetic alpha-human
atrial natriuretic peptide
(alpha-hANP) were studied in eight patients with congestive heart failure. alpha-hANP caused significant reductions in mean blood pressure and systemic vascular resistance. These responses were sustained up to 90 minutes and not accompanied by reflex tachycardia. Cardiac index and
stroke
volume index increased significantly at 90 minutes and pulmonary capillary wedge pressure, pulmonary arterial pressure, and mean right atrial pressure remained unchanged. Urine volume, urinary sodium excretion, creatinine clearance, and fractional excretion of sodium increased significantly, but fractional excretion of potassium and phosphate did not change. Elevated plasma renin activity, plasma aldosterone, and norepinephrine were suppressed after the injection of alpha-hANP. The bolus injection of this peptide has moderately hypotensive, vasorelaxant, and natriuretic effects in patients with congestive heart failure.
...
PMID:Hemodynamic, renal, and hormonal responses to alpha-human atrial natriuretic peptide in patients with congestive heart failure. 295 95
1. Plasma concentrations of
atrial natriuretic peptide
(
ANP
) and antidiuretic hormone (ADH) were measured in conscious
stroke
-prone spontaneously hypertensive (SPR), spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats before and after acute volume expansion or haemorrhage. 2. Plasma
ANP
concentration was reduced to one-third of resting values 30 min after a 1.5% haemorrhage (1.5 ml of blood per 100 g bodyweight). Plasma ADH concentration rose immediately 50-fold on haemorrhage and remained elevated at 30 min. 3. Plasma
ANP
concentration increased 2.5-fold relative to resting values 1 min after infusion of 2.0 ml per 100 g 5% dextrose; after 10 min plasma
ANP
remained elevated. Plasma ADH concentration tended to fall on volume expansion although no significant decrease was observed. 4. There was no difference in the basal levels of
ANP
and ADH, or in the changes produced by alterations in blood volume, in hypertensive SPR and SHR compared with normotensive WKY. 5. Thus, plasma
ANP
concentrations moved in opposite directions in response to two physiological stimuli: volume expansion and haemorrhage. Reciprocal changes were observed in plasma ADH.
...
PMID:Complementary changes in plasma atrial natriuretic peptide and antidiuretic hormone concentrations in response to volume expansion and haemorrhage: studies in conscious normotensive and spontaneously hypertensive rats. 295 21
In an animal preparation of congestive heart failure in the dog, during the development of cardiac failure due to rapid right ventricular pacing we observed significant decreases in cardiac output and arterial pressure and increases in pulmonary arterial and right atrial pressure. We also observed a related increase in right atrial pressure and increases in plasma levels of
atrial natriuretic peptide
(
ANP
) and cyclic guanosine monophosphate (c-GMP). Ultrastructure changes in the atrial myoendocrine cells indicated extreme stimulation of the secretory apparatus of
ANP
. The response of hemodynamic, renal, and hormonal variables was investigated after incremental infusions (0.01, 0.03, 0.1, 0.3, and 0.06 microgram/kg/min) of exogenous
ANP
. In healthy animals
ANP
significantly decreased mean arterial pressure, cardiac output,
stroke
volume, and right atrial pressure without changing heart rate or peripheral vascular resistance. As expected, we found a striking increase in urine flow and urinary excretion of sodium, chloride, magnesium and calcium and a smaller increase in potassium excretion.
ANP
suppressed renin secretion, and increased renal plasma flow, glomerular filtration rate, and filtration fraction. In dogs with heart failure
ANP
caused a small reduction in mean arterial pressure. No effect was seen on other hemodynamic variables or plasma renin concentration. The excretory effects on the kidneys were completely absent, and smaller increases in glomerular filtration rate and filtration fraction were observed. We found no difference between healthy dogs and animals with heart failure with respect to the secretion of c-GMP during
ANP
infusions in relation to the plasma levels of
ANP
. This suggests an intracellular defect that prevents the mediation of the hormonal signal into biological action in the presence of heart failure.
...
PMID:Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. 296 88
The present study examines the effects of intravenous infusion of
atrial natriuretic peptide
(
ANP
) on blood pressure, heart rate, cardiac output, sodium excretion and urine output in conscious, chronically instrumented sheep. Human
ANP
(1-28) was infused into the jugular vein (I.V.) for 60 min at 20, 50, 100 and 500 micrograms/h.
ANP
caused a decrease in blood pressure at all doses which was associated with a reduction in
stroke
volume and cardiac output. There was also a decrease in right atrial pressure. At the two higher rates of infusion an increase in both heart rate and calculated total peripheral resistance was observed. These data are consistent with
ANP
acting on the venous side of the circulation to produce venodilatation, and a reduction in venous return,
stroke
volume and cardiac output. The increases in urinary sodium excretion and urine output observed when
ANP
was infused I.V. at 100 micrograms/h for 60 min were small. The data suggest that the minimum dose for effects on the cardiovascular system (20 micrograms/h) is less than that required to produce renal effects (100 micrograms/h).
ANP
has potent effects on the cardiovascular system in conscious sheep, exerting its effect on blood pressure primarily by its action on the venous circulation and on cardiac output.
...
PMID:Hemodynamic effects of atrial natriuretic peptide in conscious sheep. 296 14
1. The effects of low dose infusion of
atrial natriuretic peptide
(
ANP
) were observed in double-blind, placebo-controlled study in six fluid-loaded volunteers. After baseline observations, hourly increments of 0.4, 2 and 10 pmol min-1 kg-1 were infused with continuous observation of heart rate, blood pressure and cardiac output. Plasma
ANP
, aldosterone, and catecholamines, and urinary volume and sodium excretion, were estimated at half-hourly intervals. 2.
ANP
infusion resulted in an increase of 35, 98 and 207% in urinary sodium excretion and of 10, 20 and 71% in urinary volume when compared with placebo. Plasma
ANP
was markedly elevated above placebo levels only during infusion of 10 pmol of
ANP
min-1 kg-1. 3. No change in heart rate of blood pressure was noted during the study, but a significant fall in
stroke
volume index was observed during active treatment. Plasma levels of aldosterone and catecholamines were not significantly different on the 2 treatment days. 4. The potent natriuretic and diuretic effects of this peptide at plasma concentrations not significantly elevated from physiological suggest a hormonal role for
ANP
in the homoeostasis of salt and water balance.
...
PMID:Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man. 296 31
The cardiac release and total body and renal clearances and the hemodynamic, renal and endocrine effects of increasing doses of
atrial natriuretic peptide
were investigated in 12 patients with severe chronic congestive heart failure. Immunoreactive arterial plasma levels of
atrial natriuretic peptide
were 10-fold higher than normal and there was no correlation between aortic
atrial natriuretic peptide
and cardiac filling pressures. The heart released
atrial natriuretic peptide
into the coronary sinus. The kidney, though a major clearance site, accounted for only 33% of the total body clearance. Administration of 0.3 micrograms/kg per min
atrial natriuretic peptide
produced significant changes in heart rate (95 +/- 4 to 85 +/- 4 beats/min) and mean arterial (92 +/- 8 to 77 +/- 9 mm Hg), right atrial (13 +/- 3 to 8 +/- 2 mm Hg) and mean pulmonary artery occluded (27 +/- 3 to 14 +/- 3 mm Hg) pressures. Atrial natriuretic peptide increased cardiac index (2.25 +/- 0.18 to 2.83 +/- 0.3 liters/min per m2) and
stroke
work index (21 +/- 1.5 to 29 +/- 3.4 g/m2), whereas systemic vascular resistance (1,424 +/- 139 to 1,033 +/- 97 dynes.s.cm(-5)) decreased. Infusion of 0.1 microgram/kg per min
atrial natriuretic peptide
increased urinary flow 128%, fractional excretion of sodium 133% and fractional excretion of potassium 35%. The filtration fraction increased from 29 +/- 2 to 31 +/- 4%. This represented a disproportionate rise in glomerular filtration rate over renal plasma flow. Plasma aldosterone and norepinephrine decreased whereas plasma renin activity remained unchanged. In association with these hemodynamic, excretory and endocrine changes, the urinary excretion of cyclic guanosine monophosphate doubled. Placebo had no effect. These results showed that, despite high circulating levels of
atrial natriuretic peptide
, administration of this hormone in heart failure is associated with potentially beneficial hemodynamic, renal and endocrine effects.
...
PMID:Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure. 296 55
Free and bound forms of
atrial natriuretic peptide
(
ANP
) in rat plasma were analysed by gel permeation chromatography combined with a radioimmunoassay (RIA) for rat
ANP
(rANP). Gel permeation chromatography showed two immunoreactive peaks in rat plasma, one corresponding to alpha-rANP, rANP(99-126), and the other eluted at a high molecular weight, clearly different from gamma-rANP, rANP(1-126). The chromatographic profile of rat plasma after incubation with synthetic alpha-rANP demonstrated that the high molecular immunoreactivity had
ANP
-binding capacity. This bound form of
ANP
was almost totally excluded following extraction procedure, therefore, the immunoreactive
ANP
(ir-ANP) measured with the extraction assay was mainly free
ANP
. On the other hand, direct RIA may detect not only the free but also the bound form of
ANP
. Using both direct RIA and the extraction method, bound forms of plasma
ANP
in spontaneously hypertensive rats (SHR) and
stroke
-prone SHR (SHRSP) were compared to normotensive Wistar Kyoto rats (WKY). Bound forms of plasma
ANP
in 20-week-old SHR and SHRSP were significantly higher than that in age-matched WKY. The ratio of free/bound form of plasma
ANP
in SHR and SHRSP also significantly increased compared to WKY, indicating a preferential increase in free
ANP
in the plasma of these hypertensive rats. These findings suggest that a bound form of
ANP
may be present in rat plasma and that it may play some pathophysiological role in the hypertension of SHR and SHRSP. Increased free
ANP
in plasma may indicate a compensatory increase in
ANP
release in these hypertensive rats.
...
PMID:Free and bound forms of atrial natriuretic peptide (ANP) in rat plasma: preferential increase of free ANP in spontaneously hypertensive rats (SHR) and stroke-prone SHR (SHRSP). 296 94
Peripheral venous plasma concentrations of immunoreactive
atrial natriuretic peptide
(irANP) were studied longitudinally in 12 women at the 12th, 24th, and 36th week of pregnancy as well as 3-5 days and 3 months post partum. Serial measurements of maternal hemodynamics were performed simultaneously with blood sampling for irANP determination. With advancing pregnancy there were significant increases (p less than 0.001) in cardiac output,
stroke
volume and heart rate, while total peripheral vascular resistance decreased (p less than 0.001). All these changes were normalized 3 months post partum. Plasma irANP increased (p less than 0.05) from 23.2 +/- 1.3 pM/l at week 12 to 25.9 +/- 1.5 pM/l at week 36 of pregnancy, and fell significantly (p less than 0.01) to 20.5 +/- 1.1 pM/l 3 months post partum. Changes in plasma irANP appear to be related to changes in maternal central hemodynamics. The changes in ANP release probably represent one of several mechanisms that maintain circulatory and volume homeostasis during normal pregnancy.
...
PMID:Plasma atrial natriuretic peptide (ANP) and maternal hemodynamic changes during normal pregnancy. 297 82
The purpose of these experiments was to compare the effects of endopeptidase inhibition with oral candoxatril on systemic and forearm hemodynamics and muscle sympathetic nerve activity with responses to a low-dose atrial natriuretic factor infusion. Eleven healthy men received at random on three separate days either intravenous saline, natriuretic factor (1.6 pmol/kg per minute) plus saline, or oral candoxatril (200 mg) plus saline. Measurements were made at baseline and 30, 60, and 90 minutes after interventions. Atrial natriuretic factor lowered diastolic pressure (P < .01), central venous pressure (P < .001), forearm blood flow (P < .05), and forearm vascular compliance (P < .05) but had no effect on systolic pressure, heart rate or its variability,
stroke
volume, sympathetic nerve activity, plasma norepinephrine, or endothelin-1. Plasma epinephrine increased (P < .01). Candoxatril lowered central venous pressure (P < .001) and increased systolic pressure (from 116 +/- 6 to 120 +/- 7 mm Hg; P < .05), endothelin (from 4.6 +/- 1.1 to 6.8 +/- 3.2 pmol/L; P < .02), and epinephrine (P < .05), without affecting any other variables. Candoxatril and atrial natriuretic factor lowered central venous pressure in healthy men without causing a reflex increase in sympathetic nerve activity or norepinephrine, yet epinephrine rose. This suggests that both interventions may specifically inhibit sympathetic nerve traffic to muscle at physiological plasma atrial natriuretic factor concentrations. However, whereas the peptide lowered blood pressure, candoxatril increased systolic pressure. These contrasting hemodynamic responses may be related to differences in plasma
atrial natriuretic peptide
concentration and to altered endothelin metabolism by candoxatril.
...
PMID:Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. 749 88
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>